Survey on long-term use of fostamatinib for chronic idiopathic thrombocytopenic purpura

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This survey evaluates the safety and efficacy of fostamatinib in Japanese patients diagnosed with chronic idiopathic thrombocytopenic purpura who are using the medication for the first time. The study is observational, meaning it will gather data on patients' experiences and outcomes under real-world conditions rather than in a controlled experimental setting. The focus is on understanding how well the drug works and its safety profile over an extended period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.

Where it's running

• Research site
  Tokyo and Japanese Other Cities, Japan Recruiting

Study contacts

• Study coordinator: Kazunori Abe, director
• Email: rinsyousiken@pharm.kissei.co.jp
• Phone: 0356843575

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fostamatinib to see if it’s safe for lung transplant patients with donor-specific antibodies

  This trial tests whether taking fostamatinib is safe for adults who have donor-specific antibodies after a lung transplant.

  Recruiting at 4 sites Phase 1 National Institutes of Health Clinical Center (CC) · Stanford, California and 3 other locations · NCT06948097

• Combining Fostamatinib with Gemcitabine and Nab-paclitaxel for Pancreatic Cancer Treatment

  This study is testing if adding a new drug called Fostamatinib to standard chemotherapy can help improve treatment outcomes for patients with operable pancreatic cancer.

  Recruiting Phase 1 University of California, San Diego · La Jolla, California · NCT06639724

• Ruxolitinib plus fostamatinib for adults with steroid-refractory chronic graft-versus-host disease

  This tests whether adding fostamatinib to ruxolitinib helps adults with chronic GvHD who haven't responded well to steroids.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT06233110

• Evaluating the safety of fostamatinib for sickle cell disease

  This study is testing whether a new medication called fostamatinib is safe for adults with stable sickle cell disease and if it can help improve their blood cell function and reduce inflammation.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05904093

• Efgartigimod IV for adolescents (12–17) with chronic immune thrombocytopenia

  This trial will try intravenous efgartigimod to see if it safely raises platelet counts in people aged 12 to 17 with chronic ITP.

  Recruiting at 26 sites Phase 2/3 argenx · Bordeaux and 25 other locations · NCT07194850

• Using fecal microbiota transplantation to treat gut disorders

  This study is testing whether a treatment that involves using healthy stool to help restore gut bacteria can improve symptoms for people with gut disorders like Crohn's disease and irritable bowel syndrome.

  Recruiting Chinese University of Hong Kong · Hong Kong, Shatin · NCT04014413

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.